https://courpharma.com/resource/bmj-neurology-open-antigen-specific-immune-therapy-cnp-106-for-treatment-of-generalised-myasthenia-gravis-rationale-and-design-of-first-in-human-randomised-controlled-trial/ 2025-05-19T15:06:36+00:00 https://courpharma.com/resource/the-journal-of-immunology-tolerogenic-immune-modifying-nanoparticles-encapsulating-multiple-recombinant-pancreatic-β-cell-proteins-prevent-onset-and-progression-of-type-1-diabetes-in-nonobese-di/ 2025-05-19T15:07:54+00:00 https://courpharma.com/resource/frontiers-masked-delivery-of-allergen-in-nanoparticles-safely-attenuates-anaphylactic-response-in-murine-models-of-peanut-allergy/ 2025-05-19T15:08:52+00:00 https://courpharma.com/resource/frontiers-specificity-of-the-t-cell-response-to-protein-biopharmaceuticals/ 2025-05-19T15:09:44+00:00 https://courpharma.com/resource/gastroenterology-tak-101-nanoparticles-induce-gluten-specific-tolerance-in-celiac-disease-a-randomized-double-blind-placebo-controlled/ 2025-05-19T15:11:03+00:00 https://courpharma.com/resource/sting-type-i-interferon-pathway-is-required-for-antigen-containing-plga-nanoparticle-and-apoptotic-cell-induced-cd4-t-cell-tolerance/ 2026-07-01T12:38:40+00:00